Avacopan for Granulomatosis with Polyangiitis

This trial tests a medication called Avacopan to observe its behavior in the body over three days. It focuses on patients with a serious lung condition related to specific types of vasculitis (inflammation of blood vessels) who require mechanical breathing assistance. This trial may suit those diagnosed with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) experiencing serious lung bleeding. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot use a strong CYP3A4 inhibitor while participating.

Research has shown that avacopan is generally well-tolerated. Patients with conditions like GPA (granulomatosis with polyangiitis) and MPA (microscopic polyangiitis) have used avacopan with good results. In one study, only 14% of patients experienced serious infections over six months, indicating a relatively low rate of serious side effects. Another study found that people taking avacopan had fewer unwanted effects and infections compared to those not taking it.

Unlike the standard of care for Granulomatosis with Polyangiitis, which typically involves corticosteroids and immunosuppressants, Avacopan offers a novel approach by targeting the complement 5a receptor. This mechanism allows it to specifically modulate the immune response without the broad immunosuppressive effects of traditional treatments. Researchers are excited about Avacopan because it could potentially reduce the need for high-dose steroids, which are known for their significant side effects. Additionally, Avacopan's administration via an NG tube in a solubilized form is unique, potentially allowing for more precise dosing and quicker onset of action.

Studies have shown that avacopan effectively treats conditions like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Specifically, research indicates that avacopan led to disease remission in about 74% of patients at week 26, compared to 71% with standard treatment. Patients using avacopan also maintained remission, with about 68% still in remission at week 52. This medication reduces the need for other drugs like glucocorticoids, which often have side effects. Overall, avacopan has proven both effective and safe in managing these conditions. Participants in this trial will receive avacopan as the investigational treatment.¹²³⁶⁷